ClinicalTrials.gg
CompletedNCT01613118DUETUpdated May 15, 2025Results posted

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

A Phase 2 interventional study of RE-021 (Sparsentan) and Irbesartan in Focal Segmental Glomerulosclerosis, sponsored by Travere Therapeutics, Inc.. Completed at 33 sites in 3 countries. Open to participants aged 8 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Travere Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
8 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.

Enrollment
6th of 56
109 · median 30
Started
2014
with 1 other
Phase 2
29 of 69
4 open now
Registered
23rd of 69
by date
Lead sponsor
5 of 69
Travere Therapeutics, Inc.

Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 6th largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2014, is one of 29 in phase 2, and was the 23rd registered.

Glomerulosclerosis, Focal Segmental

106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.

Browse Glomerulosclerosis, Focal Segmental studies →

Open to participants now

18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.

This study: 8 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, or all of them as a file.
02

Study summary

This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).

Read the detailed description

Focal segmental glomerulosclerosis (FSGS) is a rare glomerular disorder which results in frank proteinuria and in some patients progression to end-stage kidney disease (ESKD) over 5-10 years. Proteinuria reduction is widely regarded to be beneficial and is considered the primary goal of treatment in FSGS and slowing its progressive course (D'Agati, et. al, 2011). Patients are currently treated with angiotensin receptor blockers (ARB) and angiotensin converting inhibitors (ACEI) to lower proteinuria with steroids, calcineurin inhibitors, and other immunosuppressive agents reserved for patients with severe proteinuria and in particular with nephrotic syndrome. Despite these therapies, many patients have nephrotic range proteinuria and new therapeutic agents are needed. Endothelin receptor antagonists (ERA) have been shown to lower proteinuria in clinical trials of diabetic nephropathy and have been speculated to be effective in FSGS.

03

Conditions studied

  • Focal Segmental Glomerulosclerosis

Keywords

  • Primary FSGS
  • Nephrotic syndrome
  • Steroid Resistant
04

Who can participate

Ages eligible
8 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -proven FSGS OR documentation of a genetic mutation in a podocyte protein associated with the disease.
  2. Urine protein/creatinine ratio (Up/C) at or above 1.0 g/g.
  3. Estimated (eGFR) >30.
  4. Mean seated blood pressure (BP) >100/60 mmHg and \<145/95 in patients >/= 18 years of age. Mean seated BP for patients \<18 years of age should be >90/60 mmHg and \<95th percentile for age, gender, and height.
  5. If a patient is taking medications (except for Rituximab or cyclophosphamide), the dose and/or levels must be stable for 1 month prior to randomization and the Investigator should not have plans to alter the regimen during the first 8 weeks of treatment, except to stabilize levels. Patients on Rituximab or cyclophosphamide will be eligible provided they have not been taking these medications for 3 months prior to randomization.
  6. US Sites: Males or females 8 to 75 years of age willing and able to provide written and/or assent, with informed consent signed by patient or parent/legal guardian.
  7. EU Sites: Males or females 18 to 75 years of age willing and able to provide written informed consent, with informed consent, signed by patient or legal guardian.

Exclusion criteria

Exclusion Criteria

  1. Patients with FSGS secondary to another condition.
  2. Patients with history of type 1 diabetes mellitus, uncontrolled type 2 diabetes mellitus (>8%), or non-fasting blood glucose >180 mg/dL at screening.
  3. Patients who have had any organ transplant.
  4. Patients with a requirement for any of the medications indicated on the list of Excluded Medications, with the exception of ACE and ARBs.
  5. Patients with a documented history of heart failure ( Class II-IV), and / or previous hospitalization for heart failure or unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites and peripheral edema. Patients with cerebrovascular disease ( or stroke) and/or coronary artery disease (hospitalization for myocardial infarction or unstable angina, new onset of angina with positive functional tests or coronary angiogram revealing stenosis, coronary revascularization procedure) within 6 months before screening.
  6. Patients with clinically significant cardiac conduction defects, including second or third degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication.
  7. Patients with jaundice, hepatitis, or known hepatobiliary disease (includes asymptomatic cholelithiasis); and/or aspartate aminotransferase >2 times the at Screening.
  8. Patients positive for (HIV), and markers indicating acute (positivity of at least one of the following: surface antigen [HBsAg], Hepatitis B "e" antigen [HBeAg], Hepatitis B virus [HBV] DNA in blood or liver, Immunoglobulin M Hepatitis B core antibody) or chronic (HBsAg and/or HBeAg and/or Hepatitis B virus [HBV] DNA positivity) HBV infection, or virus (HCV) infection (reactive anti-HCV antibody and/or HCV RNA). Testing at screening is only required for patients >/= 18 years of age.
  9. History of other than adequately treated basal cell or squamous cell skin cancer within the past 5 years.
  10. Patients with hemodynamically significant valvular disease.
  11. Hematocrit (HCT) \<27 or (Hgb) \<9.
  12. Potassium >5.5 mEq/L.
  13. Patients >18 years of age with Estimated (eGFR) ≥60 ml mL/min who have N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥200 pg/mL (57.8 pmol/L). For patients >18 years of age with eGFR \<60 mL/min, the following parameters requiring echocardiography (ECHO) at screening should be used for exclusion:

    1. NT-proBNP ≥300 pg/mL in patients >18 years of age with eGFR 45 59.9 mL/min
    2. NT-proBNP = 200-299 pg/mL in patients >18 years of age with eGFR 45 59.9 mL/min, and abnormal (EF \<55) and/or diastolic dysfunction on ECHO
    3. NT-proBNP ≥400 pg/mL in patients >18 years of age with eGFR 30.0 44.9 mL/min
    4. NT-proBNP = 200-399 pg/mL in patients >18 years of age with eGFR 30.0 44.9 mL/min, and abnormal ejection fraction (EF \<55) and/or diastolic dysfunction on ECHO.
  14. Patients >/= 18 years of age with (BMI) >40. Patients \<18 years of age with a BMI in the 99% percentile plus 5 units.
  15. Patients who have abnormal clinical laboratory values at Screening, which are designated by the Principal Investigator as clinically significant.
  16. Patients with a history of drug or alcohol abuse within the past two years.
  17. Patients with a history of an allergic response to any angiotensin II antagonist or endothelin receptor antagonist.
  18. Women who are pregnant or breastfeeding.
  19. Women of (WOCBP) who are unwilling or unable to use two reliable methods of , with at least one being highly reliable (e.g. oral, implanted or injected contraceptive hormones or an intrauterine device) and one being a barrier method, in order to avoid pregnancy for the entire study period and for 90 days post study participation. WOCBP, defined as all women physiologically capable of becoming pregnant, includes any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral ovariectomy) or is not (defined as amenorrhea >12 consecutive months and for women on hormone replacement therapy, only with documented plasma follicle stimulating hormone level greater than 35 mIU/mL). Women using oral, implanted or injected contraceptive hormones, an intrauterine device, barrier methods (diaphragm, condoms, spermicidal) to prevent pregnancy, practicing abstinence or where the partner is sterile (e.g. vasectomy) As well as postmenopausal women who have fertilized eggs implanted are also considered WOCBP.
  20. Patients who have participated in another drug study within 28 days prior to screening, or who will participate in another drug study during the course of this study.
  21. Prior exposure to Sparsentan, dual acting receptor antagonist (DARA), or PS433540.
  22. Patients who are unable to comply with the study procedures and assessments, including the ability swallow the study drug or control capsules.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    RE-021 (Sparsentan) 200 mg - Double-Blind Period

    RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg. Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration.

    Drug: RE-021 (Sparsentan)

  • Experimental
    RE-021 (Sparsentan) 400 mg - Double-Blind Period

    RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg. Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration.

    Drug: RE-021 (Sparsentan)

  • Experimental
    RE-021 (Sparsentan) 800 mg - Double-Blind Period

    RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg. Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration.

    Drug: RE-021 (Sparsentan)

  • Active comparator
    Irbesartan 300 mg - Double-Blind Period

    The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks. Patients at \</= 50kg will receive 150mg irbesartan for the 8 week duration.

    Drug: Irbesartan

  • Experimental
    RE-021 (Sparsentan) - Open-Label Extension Period

    Includes all subjects who completed the Double-Blind period and enrolled in the Open-Label Extension period of the study. All subjects who completed the Double-Blind period were evaluated for response and safety at the Week 8 visit to determine eligibility for continued treatment on their assigned doses in an Open-Label Extension period for up to 496 additional weeks. Subjects treated with irbesartan during the Double-Blind period were offered sparsentan treatment at the dose they would have received according to the Double-Blind dose cohort in which they were enrolled.

    Drug: RE-021 (Sparsentan)

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change in Urine Protein/Creatinine (Up/C)

    Primary efficacy objective is to determine the change in UP/C in FSGS patients receiving RE-021 (Sparsentan) from baseline to 8 weeks over a range of dose levels compared to treatment with irbesartan as active control.

    Time frame: 8 weeks

Secondary outcomes

  1. Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE)

    The secondary efficacy endpoint is the proportion of FSGS patients achieving FPRE (experiencing a UP/C ratio ≤1.5 g/g and \>40% reduction from baseline in Up/C) at Week 8 over a range of dose levels compared to treatment with irbesartan as active control.

    Time frame: 8 weeks

07

Results

Posted Jul 27, 2021

Participant flow

Double-blind
Participant flow — Double-blind
MilestoneRE-021 (Sparsentan) 200 mg - Double-Blind PeriodRE-021 (Sparsentan) 400 mg - Double-Blind PeriodRE-021 (Sparsentan) 800 mg - Double-Blind PeriodIrbesartan 300 mg - Double-Blind PeriodRE-021 (Sparsentan) - Open-Label Extension Period
Started132634360
Completed132332350
Not completed03210
Open-label Extension
Participant flow — Open-label Extension
MilestoneRE-021 (Sparsentan) 200 mg - Double-Blind PeriodRE-021 (Sparsentan) 400 mg - Double-Blind PeriodRE-021 (Sparsentan) 800 mg - Double-Blind PeriodIrbesartan 300 mg - Double-Blind PeriodRE-021 (Sparsentan) - Open-Label Extension Period
Started0000103
Active at study end000030
Completed00001
Not completed0000102

Outcome measures

PrimaryPercent Change in Urine Protein/Creatinine (Up/C)

Primary efficacy objective is to determine the change in UP/C in FSGS patients receiving RE-021 (Sparsentan) from baseline to 8 weeks over a range of dose levels compared to treatment with irbesartan as active control.

Time frame:
8 weeks
Reported as:
Geometric least squares mean · percent change
Percent Change in Urine Protein/Creatinine (Up/C)
percent changeRE-021 (Sparsentan) 200, 400, 800 mg PooledIrbesartan 300 mg PooledRE-021 (Sparsentan) 400 and 800 mg PooledRE-021 (Sparsentan) 200mgRE-021 (Sparsentan) 400mgRE-021 (Sparsentan) 800mg
Percent Change in Urine Protein/Creatinine (Up/C)-44.8 (-52.7 to -35.7)-18.5 (-34.6 to 1.7)-47.4 (-56.3 to -36.9)-33.1 (-49.3 to -11.6)-52.7 (-64.3 to -37.2)-41.3 (-54.4 to -24.4)
SecondaryPercentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE)

The secondary efficacy endpoint is the proportion of FSGS patients achieving FPRE (experiencing a UP/C ratio ≤1.5 g/g and \>40% reduction from baseline in Up/C) at Week 8 over a range of dose levels compared to treatment with irbesartan as active control.

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE)
percentage of patientsRE-021 (Sparsentan) 200, 400, 800 mg PooledIrbesartan 300 mg PooledRE-021 (Sparsentan) 400 and 800 mg PooledRE-021 (Sparsentan) 200 mgRE-021 (Sparsentan) 400 mgRE-021 (Sparsentan) 800 mg
Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE)28.139.3831.3715.3838.1026.67

Adverse events

Collected over For double-blind treatment arms: 8 weeks. For all sparsentan analysis including the open-label extension period: up to 508 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RE-021 (Sparsentan) 200 mg - Double-Blind Period0/13 (0%)0/13 (0%)11/13 (84.6%)
RE-021 (Sparsentan) 400 mg - Double-Blind Period0/26 (0%)0/26 (0%)17/26 (65.4%)
RE-021 (Sparsentan) 800 mg - Double-Blind Period0/34 (0%)2/34 (5.9%)27/34 (79.4%)
Irbesartan 300 mg - Double-Blind Period0/36 (0%)1/36 (2.8%)26/36 (72.2%)
All Sparsentan (Double-Blind and Open-Label Extension)0/108 (0%)48/108 (44.4%)104/108 (96.3%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventRE-021 (Sparsentan) 200 mg - Double-Blind PeriodRE-021 (Sparsentan) 400 mg - Double-Blind PeriodRE-021 (Sparsentan) 800 mg - Double-Blind PeriodIrbesartan 300 mg - Double-Blind PeriodAll Sparsentan (Double-Blind and Open-Label Extension)
Acute kidney injuryRenal and urinary disorders0/130/260/340/3610/108
COVID-19Infections and infestations0/130/260/340/3610/108
PneumoniaInfections and infestations0/130/260/340/364/108
Chest painGeneral disorders0/130/260/340/364/108
Drug withdrawal syndromeGeneral disorders0/130/261/340/361/108
Sinus bradycardiaCardiac disorders0/130/261/340/361/108
SyncopeNervous system disorders0/130/261/340/363/108
ApnoeaRespiratory, thoracic and mediastinal disorders0/130/261/340/361/108
Pulse absentInvestigations0/130/261/340/361/108
ProteinuriaRenal and urinary disorders0/130/260/340/363/108
Most frequent other events
Showing 10 of 67
Most frequent other events
EventRE-021 (Sparsentan) 200 mg - Double-Blind PeriodRE-021 (Sparsentan) 400 mg - Double-Blind PeriodRE-021 (Sparsentan) 800 mg - Double-Blind PeriodIrbesartan 300 mg - Double-Blind PeriodAll Sparsentan (Double-Blind and Open-Label Extension)
HeadacheNervous system disorders3/132/269/347/3632/108
Oedema peripheralGeneral disorders1/132/262/341/3630/108
DiarrhoeaGastrointestinal disorders1/131/264/341/3627/108
NauseaGastrointestinal disorders1/133/265/343/3626/108
HypotensionVascular disorders1/133/266/343/3623/108
HyperkalaemiaMetabolism and nutrition disorders1/130/260/342/3622/108
DizzinessNervous system disorders0/134/266/344/3619/108
VomitingGastrointestinal disorders0/133/263/341/3619/108
ArthralgiaMusculoskeletal and connective tissue disorders0/130/260/341/3619/108
HypertensionVascular disorders0/130/260/341/3619/108

Baseline characteristics

Age, Continuous
Age, Continuous(years)RE-021 (Sparsentan) 200 mg - Double-Blind PeriodRE-021 (Sparsentan) 400 mg - Double-Blind PeriodRE-021 (Sparsentan) 800 mg - Double-Blind PeriodIrbesartan 300 mg - Double-Blind PeriodTotal
Mean42.8 ± 14.3638.3 ± 16.7835.9 ± 17.6834.1 ± 15.9636.7 ± 16.54
Sex: Female, Male
Sex: Female, Male(Participants)RE-021 (Sparsentan) 200 mg - Double-Blind PeriodRE-021 (Sparsentan) 400 mg - Double-Blind PeriodRE-021 (Sparsentan) 800 mg - Double-Blind PeriodIrbesartan 300 mg - Double-Blind PeriodTotal
Female69171749
Male717171960
08

Study locations

33 sites
  • Balboa Nephrology Medical Group
    San Diego, California 92123, United States
  • Los Angeles Biomedical Research Institute
    Torrance, California 90502, United States
  • Colorado Kidney Care
    Denver, Colorado 80230, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Miami Children's Hospital
    Miami, Florida 33155, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • Renal and Transplant Associates of New England, PC
    Springfield, Massachusetts 01107, United States
  • University of Minnesota
    Minneapolis, Minnesota 55454, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • SUNY Stony Brook Hospital
    Stony Brook, New York 11794-8111, United States
  • UNC Kidney Center, Pediatrics
    Chapel Hill, North Carolina 27599, United States
  • University North Carolina (UNC) Kidney Center
    Chapel Hill, North Carolina 27599, United States
  • Akron Nephrology Associates
    Akron, Ohio 44302, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Unversity of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Northeast Clinical Research Center
    Bethlehem, Pennsylvania 18017, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Temple University School of Medicine
    Philadelphia, Pennsylvania 19140, United States
  • University of Pennsylvania, Perelman School of Medicine
    Philadelphia, Pennsylvania 19140, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Clinical Advancement Center
    San Antonio, Texas 78215, United States
  • Southern Utah Kidney and Hypertension Center
    St. George, Utah 84790, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Catholic Health Initiatives Franciscan
    Tacoma, Washington 98405, United States
  • Marshfield Clinic Research Foundation
    Marshfield, Wisconsin 54449, United States
  • General Teaching Hospital Prague
    Prague, Czechia
  • Azienda Ospedaliero Universitaria Policlinico di Bari
    Bari, 70124, Italy
  • Azienda Ospedaliero Universitaria Careggi
    Florence, 50134, Italy
  • IRCCS Istituti Clinici Maugeri
    Pavia, 27100, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, 00168, Italy
09

References and documents

Publications

  • D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011 Dec 22;365(25):2398-411. doi: 10.1056/NEJMra1106556. No abstract available. PubMed 22187987 ↗
  • Campbell KN, Gesualdo L, Murphy E, Rheault MN, Srivastava T, Tesar V, Komers R, Trachtman H. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety. Kidney Med. 2024 Apr 26;6(6):100833. doi: 10.1016/j.xkme.2024.100833. eCollection 2024 Jun. PubMed 38831932 ↗
  • Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091. PubMed 30361325 ↗
  • Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2025 May 8;5(5):CD003594. doi: 10.1002/14651858.CD003594.pub7. PubMed 40337980 ↗
  • Omachi K, O'Carroll C, Miner JH. PPAR delta Agonism Ameliorates Renal Fibrosis in an Alport Syndrome Mouse Model. Kidney360. 2023 Mar 1;4(3):341-348. doi: 10.34067/KID.0006662022. PubMed 36657027 ↗
  • Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3. PubMed 35224732 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jun 2016, 27 months.

Results were first posted in Jul 2021, 5 years 1 month after primary completion.

Of 17 phase 2 interventional studies under Glomerulosclerosis, Focal Segmental, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2012
First posted
Jun 6, 2012
StartActual
Mar 2014
Primary completionActual
Jun 2016
CompletionActual
Mar 25, 2024
Results first posted
Jul 27, 2021
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01613118
Lead sponsor
Travere Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 6, 2012
Start date
Mar 2014
Primary completion
Jun 2016
Completion
Mar 25, 2024
Results posted
Jul 27, 2021
Last update
May 15, 2025

Study contacts

Howard Trachtman, M.D.
principal investigator · NYU School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sparsentan

Start the discussion